249 related articles for article (PubMed ID: 18392391)
21. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
Udvary E; Papp JG; Végh A
Br J Pharmacol; 1995 Feb; 114(3):656-61. PubMed ID: 7735692
[TBL] [Abstract][Full Text] [Related]
22. [Levosimendan. Clinical indications of a new vasoactive substance].
Braun JP; Döpfmer U; Kastrup M; Roots I; Borges A; Schneider M; Dohmen P; Kox W; Spies C
Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
[TBL] [Abstract][Full Text] [Related]
23. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
[TBL] [Abstract][Full Text] [Related]
24. Sustained hemodynamic effects of intravenous levosimendan.
Kivikko M; Lehtonen L; Colucci WS
Circulation; 2003 Jan; 107(1):81-6. PubMed ID: 12515747
[TBL] [Abstract][Full Text] [Related]
25. The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
Celik T; Iyisoy A; Yuksel UC; Kardesoglu E
Int J Cardiol; 2008 Aug; 128(1):97-9; authr reply 100-2. PubMed ID: 18501448
[TBL] [Abstract][Full Text] [Related]
26. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
[TBL] [Abstract][Full Text] [Related]
27. Intermittent levosimendan treatment in patients with severe congestive heart failure.
Tuomainen PO; Magga J; Timonen P; Miettinen K; Kurttila M; Vanninen E; Laitinen T; Timonen K; Punnonen K; Parviainen I; Uusaro A; Vuolteenaho O; Kivikko M; Peuhkurinen K
Clin Res Cardiol; 2013 Jul; 102(7):485-93. PubMed ID: 23503714
[TBL] [Abstract][Full Text] [Related]
28. Heart failure update.
Gomes UC; Cleland JG
Eur J Heart Fail; 1999 Aug; 1(3):301-2. PubMed ID: 10935680
[TBL] [Abstract][Full Text] [Related]
29. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
[TBL] [Abstract][Full Text] [Related]
30. How to treat acute decompensated heart failure in the 'beta-blocker era'?
Marcondes-Braga FG; Mangini S; Ayub-Ferreira SM; Bocchi EA; Bacal F
Eur J Heart Fail; 2010 Aug; 12(8):893-4. PubMed ID: 20675672
[No Abstract] [Full Text] [Related]
31. Safety and efficacy of levosimendan in patients with cardiac amyloidosis.
Aimo A; Rapezzi C; Arzilli C; Vergaro G; Emdin M
Eur J Intern Med; 2020 Oct; 80():114-116. PubMed ID: 32631802
[No Abstract] [Full Text] [Related]
32. Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study).
Altenberger J; Parissis JT; Ulmer H; Poelzl G;
Eur J Heart Fail; 2010 Feb; 12(2):186-92. PubMed ID: 20083626
[TBL] [Abstract][Full Text] [Related]
33. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
Follath F; Franco F; Cardoso JS
Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
[TBL] [Abstract][Full Text] [Related]
34. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
35. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery.
Labriola C; Siro-Brigiani M; Carrata F; Santangelo E; Amantea B
Int J Clin Pharmacol Ther; 2004 Apr; 42(4):204-11. PubMed ID: 15124978
[TBL] [Abstract][Full Text] [Related]
36. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
37. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.
Parissis JT; Panou F; Farmakis D; Adamopoulos S; Filippatos G; Paraskevaidis I; Venetsanou K; Lekakis J; Kremastinos DT
Am J Cardiol; 2005 Aug; 96(3):423-6. PubMed ID: 16054474
[TBL] [Abstract][Full Text] [Related]
38. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics.
García-González MJ; Domínguez-Rodríguez A; Ferrer-Hita JJ; Abreu-González P; Muñoz MB
Eur J Heart Fail; 2006 Nov; 8(7):723-8. PubMed ID: 16492404
[TBL] [Abstract][Full Text] [Related]
39. Myocardial efficiency during levosimendan infusion in congestive heart failure.
Ukkonen H; Saraste M; Akkila J; Knuuti J; Karanko M; Iida H; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
Clin Pharmacol Ther; 2000 Nov; 68(5):522-31. PubMed ID: 11103755
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of levosimendan in patients with acute heart failure.
Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
